Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Int J Med Microbiol ; 307(1): 1-10, 2017 Jan.
Article in English | MEDLINE | ID: mdl-27989665

ABSTRACT

The assembly of the bacterial cell wall requires synchronization of a multitude of biosynthetic machineries and regulatory networks. The eukaryotic-like serine/threonine kinase PknB has been implicated in coordinating cross-wall formation, autolysis and cell division in Staphylococcus aureus. However, the signal molecule sensed by this kinase remained elusive so far. Here, we provide compelling biochemical evidence that PknB interacts with the ultimate cell wall precursor lipid II, triggering kinase activity. Moreover, we observed crosstalk of PknB with the two component system WalKR and identified the early cell division protein FtsZ as another PknB phosphorylation substrate in S. aureus. In agreement with the implied role in regulation of cell envelope metabolism, we found PknB to preferentially localize to the septum of S. aureus and the PASTA domains to be crucial for recruitment to this site. The data provide a model for the contribution of PknB to control cell wall metabolism and cell division.


Subject(s)
Bacterial Proteins/metabolism , Cell Wall/metabolism , Protein Serine-Threonine Kinases/metabolism , Staphylococcus aureus/enzymology , Staphylococcus aureus/metabolism , Uridine Diphosphate N-Acetylmuramic Acid/analogs & derivatives , Cytoskeletal Proteins/metabolism , Protein Binding , Protein Interaction Maps , Uridine Diphosphate N-Acetylmuramic Acid/metabolism
2.
Antimicrob Agents Chemother ; 60(11): 6510-6517, 2016 11.
Article in English | MEDLINE | ID: mdl-27550357

ABSTRACT

Teixobactin represents the first member of a newly discovered class of antibiotics that act through inhibition of cell wall synthesis. Teixobactin binds multiple bactoprenol-coupled cell wall precursors, inhibiting both peptidoglycan and teichoic acid synthesis. Here, we show that the impressive bactericidal activity of teixobactin is due to the synergistic inhibition of both targets, resulting in cell wall damage, delocalization of autolysins, and subsequent cell lysis. We also find that teixobactin does not bind mature peptidoglycan, further increasing its activity at high cell densities and against vancomycin-intermediate Staphylococcus aureus (VISA) isolates with thickened peptidoglycan layers. These findings add to the attractiveness of teixobactin as a potential therapeutic agent for the treatment of infection caused by antibiotic-resistant Gram-positive pathogens.


Subject(s)
Anti-Bacterial Agents/pharmacology , Cell Wall/drug effects , Depsipeptides/pharmacology , Staphylococcus aureus/drug effects , Cell Wall/metabolism , Cell Wall/ultrastructure , Drug Delivery Systems , Microbial Sensitivity Tests , N-Acetylmuramoyl-L-alanine Amidase/metabolism , Peptidoglycan/metabolism , Staphylococcus aureus/metabolism , Staphylococcus aureus/ultrastructure , Teichoic Acids/metabolism , Terpenes/metabolism , Vancomycin Resistance/drug effects
3.
J Biol Chem ; 291(5): 2535-46, 2016 Jan 29.
Article in English | MEDLINE | ID: mdl-26620564

ABSTRACT

Screening of new compounds directed against key protein targets must continually keep pace with emerging antibiotic resistances. Although periplasmic enzymes of bacterial cell wall biosynthesis have been among the first drug targets, compounds directed against the membrane-integrated catalysts are hardly available. A promising future target is the integral membrane protein MraY catalyzing the first membrane associated step within the cytoplasmic pathway of bacterial peptidoglycan biosynthesis. However, the expression of most MraY homologues in cellular expression systems is challenging and limits biochemical analysis. We report the efficient production of MraY homologues from various human pathogens by synthetic cell-free expression approaches and their subsequent characterization. MraY homologues originating from Bordetella pertussis, Helicobacter pylori, Chlamydia pneumoniae, Borrelia burgdorferi, and Escherichia coli as well as Bacillus subtilis were co-translationally solubilized using either detergent micelles or preformed nanodiscs assembled with defined membranes. All MraY enzymes originating from Gram-negative bacteria were sensitive to detergents and required nanodiscs containing negatively charged lipids for obtaining a stable and functionally folded conformation. In contrast, the Gram-positive B. subtilis MraY not only tolerates detergent but is also less specific for its lipid environment. The MraY·nanodisc complexes were able to reconstitute a complete in vitro lipid I and lipid II forming pipeline in combination with the cell-free expressed soluble enzymes MurA-F and with the membrane-associated protein MurG. As a proof of principle for future screening platforms, we demonstrate the inhibition of the in vitro lipid II biosynthesis with the specific inhibitors fosfomycin, feglymycin, and tunicamycin.


Subject(s)
Bacterial Proteins/chemistry , Monosaccharides/biosynthesis , Oligopeptides/biosynthesis , Transferases/chemistry , Uridine Diphosphate N-Acetylmuramic Acid/analogs & derivatives , Bacillus subtilis/enzymology , Biosynthetic Pathways , Bordetella pertussis/enzymology , Borrelia burgdorferi/enzymology , Cell Wall/chemistry , Cell-Free System , Chlamydophila pneumoniae/enzymology , Cytoplasm/chemistry , DNA/chemistry , Detergents/chemistry , Escherichia coli/enzymology , Fosfomycin/chemistry , Helicobacter pylori/enzymology , Micelles , Peptides/chemistry , Peptidoglycan/chemistry , Proteins/chemistry , Recombinant Proteins/chemistry , Transferases (Other Substituted Phosphate Groups) , Tunicamycin/chemistry , Uridine Diphosphate N-Acetylmuramic Acid/biosynthesis
5.
Nature ; 517(7535): 455-9, 2015 Jan 22.
Article in English | MEDLINE | ID: mdl-25561178

ABSTRACT

Antibiotic resistance is spreading faster than the introduction of new compounds into clinical practice, causing a public health crisis. Most antibiotics were produced by screening soil microorganisms, but this limited resource of cultivable bacteria was overmined by the 1960s. Synthetic approaches to produce antibiotics have been unable to replace this platform. Uncultured bacteria make up approximately 99% of all species in external environments, and are an untapped source of new antibiotics. We developed several methods to grow uncultured organisms by cultivation in situ or by using specific growth factors. Here we report a new antibiotic that we term teixobactin, discovered in a screen of uncultured bacteria. Teixobactin inhibits cell wall synthesis by binding to a highly conserved motif of lipid II (precursor of peptidoglycan) and lipid III (precursor of cell wall teichoic acid). We did not obtain any mutants of Staphylococcus aureus or Mycobacterium tuberculosis resistant to teixobactin. The properties of this compound suggest a path towards developing antibiotics that are likely to avoid development of resistance.


Subject(s)
Anti-Bacterial Agents/pharmacology , Depsipeptides/pharmacology , Drug Resistance, Microbial , Microbial Viability/drug effects , Mycobacterium tuberculosis/drug effects , Staphylococcus aureus/drug effects , Animals , Anti-Bacterial Agents/biosynthesis , Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/isolation & purification , Betaproteobacteria/chemistry , Betaproteobacteria/genetics , Biological Products/chemistry , Biological Products/isolation & purification , Biological Products/pharmacology , Cell Wall/chemistry , Cell Wall/drug effects , Cell Wall/metabolism , Depsipeptides/biosynthesis , Depsipeptides/chemistry , Depsipeptides/isolation & purification , Disease Models, Animal , Drug Resistance, Microbial/genetics , Female , Mice , Microbial Sensitivity Tests , Molecular Sequence Data , Multigene Family/genetics , Mycobacterium tuberculosis/cytology , Mycobacterium tuberculosis/genetics , Peptidoglycan/biosynthesis , Staphylococcal Infections/drug therapy , Staphylococcal Infections/microbiology , Staphylococcus aureus/chemistry , Staphylococcus aureus/cytology , Staphylococcus aureus/genetics , Teichoic Acids/biosynthesis , Time Factors
6.
Antimicrob Agents Chemother ; 59(2): 772-81, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25403671

ABSTRACT

Oritavancin is a semisynthetic derivative of the glycopeptide antibiotic chloroeremomycin with activity against Gram-positive pathogens, including vancomycin-resistant staphylococci and enterococci. Compared to vancomycin, oritavancin is characterized by the presence of two additional residues, a hydrophobic 4'-chlorobiphenyl methyl moiety and a 4-epi-vancosamine substituent, which is also present in chloroeremomycin. Here, we show that oritavancin and its des-N-methylleucyl variant (des-oritavancin) effectively inhibit lipid I- and lipid II-consuming peptidoglycan biosynthesis reactions in vitro. In contrast to that for vancomycin, the binding affinity of oritavancin to the cell wall precursor lipid II appears to involve, in addition to the D-Ala-D-Ala terminus, other species-specific binding sites of the lipid II molecule, i.e., the crossbridge and D-isoglutamine in position 2 of the lipid II stem peptide, both characteristic for a number of Gram-positive pathogens, including staphylococci and enterococci. Using purified lipid II and modified lipid II variants, we studied the impact of these modifications on the binding of oritavancin and compared it to those of vancomycin, chloroeremomycin, and des-oritavancin. Analysis of the binding parameters revealed that additional intramolecular interactions of oritavancin with the peptidoglycan precursor appear to compensate for the loss of a crucial hydrogen bond in vancomycin-resistant strains, resulting in enhanced binding affinity. Augmenting previous findings, we show that amidation of the lipid II stem peptide predominantly accounts for the increased binding of oritavancin to the modified intermediates ending in D-Ala-D-Lac. Corroborating our conclusions, we further provide biochemical evidence for the phenomenon of the antagonistic effects of mecA and vanA resistance determinants in Staphylococcus aureus, thus partially explaining the low frequency of methicillin-resistant S. aureus (MRSA) acquiring high-level vancomycin resistance.


Subject(s)
Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/pharmacology , Glycopeptides/chemistry , Glycopeptides/pharmacology , Enterococcus faecium/chemistry , Lipoglycopeptides , Microbial Sensitivity Tests , Staphylococcus aureus/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...